Tags

Type your tag names separated by a space and hit enter

Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: results from a noninterventional study.
Allergy Asthma Proc. 2015 Jan-Feb; 36(1):40-7.AA

Abstract

The efficacy of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) has been well established in controlled clinical trials. This study was designed to assess the use of MP29-02 and its effectiveness in routine clinical practice. This was a German multicenter, prospective, noninterventional study, including 1781 allergic rhinitis (AR) patients. Eligible patients (i.e., acute AR symptoms and visual analog scale [VAS] score >50 mm) were included, assigned MP29-02 at baseline, and reassessed after ∼14 days. Patients assessed symptom control using a VAS from 0 (not at all bothersome) to 100 mm (very bothersome) in the morning before MP29-02 use, on days 0, 1, 3, and 7 and after ∼ 14 days. Patients' perceived levels of disease control were assessed on day 3. The Youden index determined patient-reported VAS score cutoffs on day 3 for "well controlled" and "partly controlled." MP29-02 reduced the VAS score from 75.4 mm (SD = 17.2) at baseline to 21.3 mm (SD = 18.3) by the last visit, a shift of 54.1 mm (SD = 24.6). One in every two patients felt their symptoms were well controlled at day 3. This perception of well-controlled symptoms at day 3 corresponded to an optimal VAS cutoff of 36 mm. On average, patients treated with MP29-02 crossed this well-controlled VAS cutoff by last visit. Similar results were found in adolescents, adults, and older adults, in those with perennial AR (PAR), seasonal AR (SAR), or PAR + SAR and in those with more and less severe disease. MP29-02 provides effective and rapid symptom control across all age groups in a real-life setting with responder rates higher than those observed in controlled clinical trials, supporting MP29-02's position as the drug of choice for the treatment for AR.

Authors+Show Affiliations

Center for Rhinology and Allergology, Wiesbaden, Germany.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25562555

Citation

Klimek, Ludger, et al. "Effectiveness of MP29-02 for the Treatment of Allergic Rhinitis in Real-life: Results From a Noninterventional Study." Allergy and Asthma Proceedings, vol. 36, no. 1, 2015, pp. 40-7.
Klimek L, Bachert C, Mösges R, et al. Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: results from a noninterventional study. Allergy Asthma Proc. 2015;36(1):40-7.
Klimek, L., Bachert, C., Mösges, R., Munzel, U., Price, D., Virchow, J. C., Wahn, U., & Bousquet, J. (2015). Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: results from a noninterventional study. Allergy and Asthma Proceedings, 36(1), 40-7. https://doi.org/10.2500/aap.2015.36.3823
Klimek L, et al. Effectiveness of MP29-02 for the Treatment of Allergic Rhinitis in Real-life: Results From a Noninterventional Study. Allergy Asthma Proc. 2015 Jan-Feb;36(1):40-7. PubMed PMID: 25562555.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: results from a noninterventional study. AU - Klimek,Ludger, AU - Bachert,Claus, AU - Mösges,Ralph, AU - Munzel,Ullrich, AU - Price,David, AU - Virchow,J Christian, AU - Wahn,Ulrich, AU - Bousquet,Jean, PY - 2015/1/7/entrez PY - 2015/1/7/pubmed PY - 2015/9/17/medline SP - 40 EP - 7 JF - Allergy and asthma proceedings JO - Allergy Asthma Proc VL - 36 IS - 1 N2 - The efficacy of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) has been well established in controlled clinical trials. This study was designed to assess the use of MP29-02 and its effectiveness in routine clinical practice. This was a German multicenter, prospective, noninterventional study, including 1781 allergic rhinitis (AR) patients. Eligible patients (i.e., acute AR symptoms and visual analog scale [VAS] score >50 mm) were included, assigned MP29-02 at baseline, and reassessed after ∼14 days. Patients assessed symptom control using a VAS from 0 (not at all bothersome) to 100 mm (very bothersome) in the morning before MP29-02 use, on days 0, 1, 3, and 7 and after ∼ 14 days. Patients' perceived levels of disease control were assessed on day 3. The Youden index determined patient-reported VAS score cutoffs on day 3 for "well controlled" and "partly controlled." MP29-02 reduced the VAS score from 75.4 mm (SD = 17.2) at baseline to 21.3 mm (SD = 18.3) by the last visit, a shift of 54.1 mm (SD = 24.6). One in every two patients felt their symptoms were well controlled at day 3. This perception of well-controlled symptoms at day 3 corresponded to an optimal VAS cutoff of 36 mm. On average, patients treated with MP29-02 crossed this well-controlled VAS cutoff by last visit. Similar results were found in adolescents, adults, and older adults, in those with perennial AR (PAR), seasonal AR (SAR), or PAR + SAR and in those with more and less severe disease. MP29-02 provides effective and rapid symptom control across all age groups in a real-life setting with responder rates higher than those observed in controlled clinical trials, supporting MP29-02's position as the drug of choice for the treatment for AR. SN - 1539-6304 UR - https://www.unboundmedicine.com/medline/citation/25562555/Effectiveness_of_MP29_02_for_the_treatment_of_allergic_rhinitis_in_real_life:_results_from_a_noninterventional_study_ L2 - https://www.ingentaconnect.com/openurl?genre=article&issn=1539-6304&volume=36&issue=1&spage=40&aulast=Klimek DB - PRIME DP - Unbound Medicine ER -